title: Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion.
abstract: To investigate the mechanism of oral carbohydrate-stimulated secretion of the two most potent incretin candidates, gastric inhibitory polypeptide (GIP) and truncated glucagon-like peptide-1 (tGLP-1), we studied the changes in the plasma levels of these peptides in five healthy men after sucrose ingestion with or without pretreatment with an alpha-D-glucosidase inhibitor (AO-128). After sucrose ingestion, plasma levels of GIP peaked at 15 min and remained high up to 120 min. Plasma levels of GLP-1 NT measured with antiserum R1043 (N-terminal specific) tended to decrease gradually and those of GLP-1 CT measured with antiserum R2337 (C-terminal specific) increased. Therefore, estimated plasma levels of tGLP-1 increased markedly within 30 min, then declined slightly over the next 60 min. After treatment with AO-128 (0.6 mg/day) for 1 week, increases in plasma glucose and insulin levels were attenuated and the increase in plasma GIP levels was diminished, while the increase in tGLP-1 levels was sustained much longer. It is concluded that GIP secretion is stimulated by glucose absorption and tGLP-1 secretion by the presence of sucrose in the gut.
authors.affiliation: Third Department of Internal Medicine, Yamagata University School of Medicine, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Fukase
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.forename: H
authors.initials: H
authors.lastname: Manaka
authors.forename: M
authors.initials: M
authors.lastname: Igarashi
authors.forename: K
authors.initials: K
authors.lastname: Yamatani
authors.forename: M
authors.initials: M
authors.lastname: Daimon
authors.forename: K
authors.initials: K
authors.lastname: Sugiyama
authors.forename: M
authors.initials: M
authors.lastname: Tominaga
authors.forename: H
authors.initials: H
authors.lastname: Sasaki
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D003511:Cyclohexanols / Q000494:pharmacology; D005749:Gastric Inhibitory Polypeptide / Q000097:blood / Q000378:metabolism*; D005934:Glucagon / Q000097:blood / Q000378:metabolism*; D052216:Glucagon-Like Peptide 1; D005947:Glucose / Q000008:administration & dosage; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D007700:Kinetics; D008297:Male; D010446:Peptide Fragments / Q000097:blood / Q000378:metabolism*; D011498:Protein Precursors / Q000097:blood / Q000378:metabolism*; D012016:Reference Values; D013395:Sucrose / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D003511:Cyclohexanols; D065089:Glycoside Hydrolase Inhibitors; D007328:Insulin; D010446:Peptide Fragments; D011498:Protein Precursors; C054577:AO 128; D013395:Sucrose; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D005947:Glucose